Genprex Inc GNPX

NAS: GNPX | ISIN: US3724461047   20/05/2024
2,440 USD (-4,31%)
(-4,31%)   20/05/2024
Grafiek Genprex Inc Grafiek Genprex Inc

Genprex Inc in het nieuws

14 mei 2024 · Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

13 mei 2024 · Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors · Persbericht

9 mei 2024 · Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner · Persbericht

1 mei 2024 · Genprex to Present and Participate at Upcoming May Investor and Industry Conferences · Persbericht

9 april 2024 · Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting · Persbericht

3 april 2024 · Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer · Persbericht

2 april 2024 · Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System · Persbericht

22 maart 2024 · Genprex Announces Closing of $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

19 maart 2024 · Genprex Announces $6.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules · Persbericht

Profiel Genprex Inc

Fabricage van farmaceutische preparaten
Farmaceutica
Gezondheidstechnologie
Productie

Website: www.genprex.com

Hoofdzetel: Austin, Texas vlag Verenigde Staten

CEO: J. Rodney Varner

Werknemers: 26

Aandelen Genprex Inc

Beurswaarde: 5,35 miljoen USD

Effecten: 2,10 miljoen

Beta: 2,46

Mijn selecties